Verquvo
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Vericiguat
- Made by
- Bayer AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of symptomatic chronic heart failure
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (VERQUVO). It describes the substance, not this exact product.
Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway.
When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling.
Following oral administration of radiolabeled vericiguat to healthy subjects, approximately 53% of the dose was excreted in urine (primarily as inactive metabolite) and 45% in feces (primarily as unchanged drug).
The absolute bioavailability of vericiguat is 93% when taken with food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-21
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Bayer AG |
|---|---|
| Active substance | Vericiguat |
| Used in | Heart, blood pressure and circulation |
| Classification | C01 · Heart, blood pressure and circulation |
| Authorised on | 2021-07-16 |
| Last updated by the regulator | 2026-04-21 |
| EMA product number | EMEA/H/C/005319 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).